

LIFE
SCIENCE
NORD



Hamburg, Schleswig-Holstein



LIFE
SCIENCE
NORD



BONEBANK: A GERMAN-DANISH BIOBANK FOR STEM CELLS IN BONE HEALING

ScanBalt Forum, Tallin,
October 2017



PROJECT IN A NUTSHELL

Start: 1th September 2015

End: 29th February 2019

Duration: 36 months

**Total project budget: 2.377.265 EUR,
1.338.876 EUR of which are Interreg funding**



Interreg
Deutschland - Danmark



PROJECT STRUCTURE

Project Partners

University Medical Centre Schleswig-Holstein, Campus Lübeck (Lead Partner)

Odense University Hospital

Stryker Trauma

Soventec

Life Science Nord

Network partners

Syddansk Sundhedsinnovation

WelfareTech

Project Management

DSN - Connecting Knowledge



OPPORTUNITIES, AMBITION AND GOALS




- Research on stem cells is driving regenerative medicine
- Availability of high-quality bone marrow stem cells for patients and research is limited today
- Innovative approach to harvest bone marrow stem cells during routine operations for fracture treatment
- Facilitating access to bone marrow stem cells and driving research and innovation in Germany-Denmark

Harvesting of bone marrow stem cells during routine operations in the university hospitals Odense and Lübeck


Cross-border biobank for bone marrow stem cells located in Odense and Lübeck

Organisational and exploitation model for the Danish-German biobank providing access to bone marrow stem cells for donators, patients, public research and companies

routine operations
e.g. fracture
treatment or joint
replacement



isolated bone
stem cells



frozen storage in a
bone bank



LIFE SCIENCE NORD

ACHIEVEMENTS SO FAR

Harvesting of 53 samples, both in Denmark and Germany

Most patients (34) are over 60 years old


Isolation of stem cells possible

Characterization profiles of stem cells vary from individual to individual




Donors/Patients

Germany
Denmark



Age

< 60 years
> 60 years



POSSIBLE APPLICATION FIELDS

Mesenchymal stem cells isolated from human bone material can be used for...

- Autologous therapy
 - Allogenic therapy
 - Stem cells for research (public or industrial)
- Isolated cells currently do not meet requirements for therapy

Business model?



CHALLENGES IN CROSS BORDER ECONOMY

- Lack of common structures for building legal entities
- Cultural differences
- Differences in the regulatory environment
- Language
- Lack of cooperation from government agencies
- Lack of common data protection (despite EU GDPR)





LIFE
SCIENCE
NORD



supported by



supported by



THANK YOU

Dr. Thomas Frahm
Life Science Nord Management GmbH
Phone: +49 40 47 19 64 22
frahm@lifesciencenord.de

